Cardiomyopathies: Diagnosis of types and stages

Acta Myologica

Volumn 23, Issue 2, 2004, Pages 97-102

  Nigro, Giovanni ^a,b,d   Comi, L I ^a,b,d   Nigro, Ge ^c   Palladino, A ^a,d   Petretta, V R ^a   Politano, L ^a,b,d  

^a Dept Exp Med/Cardiomyol/Med G ^*  (Italy)

^b Ctro Eccellenza Malat Cardiovasc   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d Sezione Scientifica Ctro G Torre   (Italy)

Author keywords

Cardiomyopathies; Genetic cardiomyopathy; Stages of primary cardiomyopathies

Indexed keywords

CALPAIN; CONNECTIN; DESMIN; LAMIN; MEROSIN; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; PHOSPHOLAMBAN; RYANODINE RECEPTOR; SARCOGLYCAN; TROPOMYOSIN; TROPONIN I; TROPONIN T; VINCULIN;

ARRHYTHMOGENESIS; ARTICLE; BONE DISEASE; CARDIOMYOPATHY; CLINICAL FEATURE; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART FAILURE; HEART MUSCLE; HEART MUSCLE FIBROSIS; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NEUROLOGIC DISEASE; RESTRICTIVE CARDIOMYOPATHY;

EID: 9344249028     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Schönberg J, Seidman CE. Many roads led to a broken heart: The genetics of dilated cardiomyopathy. Am J Hum Genet 2001;69:249-60.
2. th Edn WB Saunders, 1997;p.1404-63.
3. th Edn) Emery AEH, Rimoin DL, editors. Churchill Livingstone, 2002;p.1342-416.
4. Davies MJ. The cardiomyopathies: An overview. Heart 2000;83:469-74.
5. Nigro G, Comi LI, Politano L, Nigro Ge. Cardiomyopathies associated with muscular dystrophies. In: Myology. Engel & Franzini-Armstrong, editors. McGraw-Hill; 2004;p.1239-56.
6. Goodwin JF, Gordon H, Hoffman A, et al. Clinical aspects of cardiomyopathy. Br Med J 1961;1:69-79.
7. Globus JH. The pathologic finding in heart muscle in progressive muscular dystrophy. Arch Neurol Psychiatry 1923;9:59-72.
8. Weisenfeld S, Messinger WJ. Cardiac involvement in progressive muscular dystrophy. Am Heart J 1952;43:170-87.
9. Perloff JK, Roberts WC, de Leon AC, et al. The distinctive electrocardiogram of Duchenne's progressive muscular dystrophy. Am J Med 1967;42:179-86.
10. de Visser M, De Voogt WG, La Rivière GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. Muscle Nerve 1992;15:591-6.
11. Hoogerwaard EM, de Voogt WG, Wilde AA, et al. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. J Neurol 1997;244:657-63.
12. Hayashi Y, Ikeda U, Ogawa T, et al: Becker-type muscular dystrophy associated with hypertrophic cardiomyopathy. Am Heart J 1994;128:1264-6.
13. Politano L, Nigro V, Nigro G, et al. Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA 1996;275:1335-8.
14. Berko BA, Swift M. X-linked dilated cardiomyopathy, N Engl J Med 1987;316:1186-91.
15. Politano L, Passamano L, Petretta VR, et al. Familial dilated cardiomyopathy associated with the typical dystrophin BMD mutation: report on two additional cases. Acta Myol 1999;18:229-36.
16. Mascarenhas DAN, Spodick DH, Chad DA, et al. Cardiomyopathy of limb-girdle muscular dystrophy. J Am Coll Cardiol 1994;24:1328-33.
17. Nigro V, Okazaki Y, Belsito A, et al. Identification of the Syrian hamster cardiomyopathy gene. Hum Mol Genet 1997;4:601-7.
18. Sakamoto A, Ono K, Abe M, et al. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, 5-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex. Proc Natl Acad Sci USA 1997;94:13873-8.
19. Van der Koii AJ, de Voogt WG, Barth PG, et al. The heart in limb-girdle muscular dystrophy. Heart 1998;79:73-7.
20. Melacini P, Fanin M, Duggan DJ, et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve 1999;22:473-9.
21. Calvo F, Teijeira S, Fernandez JM, et al. Evaluation of heart involvement in gamma-sarcoglycanopathy (LGMD2C). A study of ten patients. Neuromuscul Disord 2000;10:560-6.
22. Politano L, Nigro V, Passamano L, et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 2001;11:178-85.
23. Bialer MG, McDaniel NL, Kelly TE, et al. Progression of cardiac disease in Emery-Dreifuss muscular dystrophy. Clin Cardiol 1991;14:411-16.
24. Di Barletta R, Ricci E, Galluzzi G, et al. Different mutations in the LMNA gene cause autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet 2000;66:1407-12.
25. Fatkin D, Mc Rae C, Sasaki T, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999;341:1715-24.
26. Muchir A, Bonne G, Van der Kool AS, et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet 2000;9:1453-9.
27. Itoh-Satoh M, Hayashi T, Nishi H, et al. Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun 2002;291:385-93.
28. Li D, Tapscoft T, Gonzales O, et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 1999;100:461-4.
29. Leonard EG. Viral myocarditis. Pediatr Infect Dis J 2004;23:665-6.
30. Maisch B, Ristic AD, Portig I, Pankuweit S. Human viral cardiomyopathy. Front Biosci 2003;8:s39.
31. Panschinger M, Chandrasekharan K, Noutsias M, et al. Viral heart disease: molecular diagnosis, clinical prognosis, and treatment strategies. Med Microbiol Immunol (Berl) 2004;193:65-9.
32. Zhang H, Li Y, McClean DR, Richardson PJ, et al. Detection of enterovirus capsid protein VP1 in myocardium from cases of myocarditis or dilated cardiomyopathy by immunohistochemistry: further evidence of enterovirus persistence in myocytes. Med Microbiol Immunol (Berl) 2004;193:109-14.
33. Giordano G, Nigro G, Valoroso L: Ricerche sulle miocarditi in corso di infezioni virali (Indagini ecografiche ed istologiche sul topo albino infettato con virus Coxackie). Minerva Cardiomiol 1959;7:38-47.
34. Iskandar SB, Loyd S, Downs CJ, Roy TM. Hepatitis C and dilated cardiomyopathy. Tenn Med 2004;97:31-3.
35. Alter P, Grimm W, Herzum M, et al. Physical exercise in patients with heart failure due to myocarditis and dilated cardiomyopathy. Herz 2004;29:391-400.
36. Takata S, Nakamura H, Umemoto S, et al. Identification of autoantibodies with the corresponding antigen for repetitive coxsackie virus infection-induced cardiomyopathy. Circ J 2004;68:677-82.
37. Kawai C. From myocarditis to cardiomyopathy: Mechanisms of inflammation and cell death: Learning from the past for the future. Circulation 1999;99:1091-100.
38. Nakamura H, Yamamura T, Umemoto S, et al. Autoimmune response in chronic ongoing myocarditis demonstrated by heterotopic cardiac transplantation in mice. Circulation 1996;94:3348-54.
39. Maisch B, Ristic AD, Hufnagel G, Pankuweit S. Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc Pathol 2002;11:112-22.
40. Nakamura H, Yamamoto T, Yamamura T, et al. Repetitive coxsackie virus infection induces cardiac dilatation in post-myocarditic mice. Jpn Circ J 1999;63:794-802.
41. Matsumori A, Kawai C: An experimental model for congestive heart failure after encephalomyocarditis virus myocarditis in mice. Circulation 1982;65:1230-5.
42. Liu PP, Mason JW. Advances in the understanding of myocarditis. Circulation 2001;104:1076-82.
43. Klein RM, Jiang H, Niederacher D, et al. Frequency and quantity of the parvovirus B 19 genome in endomyocardial biopsies from patients with suspected myocarditis or idiopathic left ventricular dysfunction. Z Kardiol 2004;93:300-9.
44. Schulze K, Becker BF, Schauer R, Schultheiss HP. Antibodies to ADP-ATP carrier, an autoantigen in myocarditis and dilated cardiomyopathy, impair cardiac function. Circulation 1990;81:959-69.
45. Magnusson Y, Marullo S, Hoyer S, et al. Mapping of a functional autoimmune epitope on the β1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990;86:1658-63.
46. Baba A, Yoshikawa T, Chino M. Characterization of antimyocardial autoantibodies in Japanese patients with dilated cardiomyopathy. Jpn Circ J 2001;65:867-73.
47. Kishimoto C, Kurokawa M, Ochiai H. Antibody-mediated immune enhancement in coxsackievirus B3 myocarditis. J Mol Cell Cardiol 2002;34:1227-38.
48. Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003;9:1477-83.
49. Portig I, Pankuweit S, Maish B. Antibodies against stress protein in sera of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1997;29:2245-51.
50. Wang Z, Liao Y, Dong J, et al. Clinical significance and pathogenic role of anti-cardiac myosin autoantibody in dilated cardiomyopathy. Chin Med J (Engl) 2003;116:499-502.
51. Noutsias M, Pauschinger M, Poller WC, et al. Current insights into the pathogenesis, diagnosis and therapy of inflammatory cardiomyopathy. Heart Fail Monit 2003;3:127-35.
52. Pankuweit S, Portig I, Maisch B. Pathophysiology of cardiac inflammation: molecular mechanisms. Herz 2002;27:669-76.
53. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail 2002;4:411-17.
54. Nigro G, Comi LI, Politano L, et al. Electrocardiographic evaluation of the P-type stage of dystrophic cardiomyopathy. Cardiomyology 1984;3:45-58.
55. Nigro G, Comi LI, Limongelli FM, et al. Prospective study of X-linked progressive muscular dystrophy in Campania. Muscle Nerve 1985;36:253-62.
56. Steare SE, Dubowitz V, Benatar A. Subclinical cardiomyopathy in Becker muscular dystrophy. Br Heart J 1992;68:304-8.
57. Comi LI, Petretta VR, De Luca F, et al. Detection of early stage of dilated cardiomyopathy in Duchenne patients by means of a new echocardiographic parameter. Acta Cardiomyol 1991;3:35-44.
58. Nigro G, Comi LI, Politano L, Bain RJI. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Intern J Cardiol 1990;26:271-7.
59. Hiromasa S, Ikeda T, Kubota K, et al. Myotonic dystrophy: Ambulatory electrocardiogram, electrophysiologic study, and echocardiographic evaluation. Am Heart J 1987;113:1482-8.
60. Forsberg H, Olofsson BO, Andersson S, et al. 24-hour electrocardiographic study in myotonic dystrophy. Cardiology 1988;75:241-9.
61. Nguyen HH, Wolfe JTD, Holmes DR Jr, Edwards WD. Pathology of the cardiac conduction system in myotonic dystrophy: A study of 12 cases. J Am Coll Cardiol 1988;11:662-71.
62. Mclay JS, Norris A, Kerr F. Could it be myotonic dystrophy? Myotonic dystrophy presenting with atrial flutter. Scott Med J 1992;37:149-50.
63. Lazarus A, Varin J, Ounnoughene Z, et al. Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy. Circulation 1999;99:1041-6.
64. Nigro Ge, Nigro G, Politano L, et al. Is the value of QT dispersion a valid method to foresee the risk of sudden death? A study in Becker patients. Heart 2002;87:156-7.
65. Towbin JA. A noninvasive means of detecting preclinical cardiomyopathy in Duchenne muscular dystrophy? JACC 2003;42:317-8.
66. Politano L, Palladino A, Petretta VR, et al. ST-segment displacement in Duchenne muscular dystrophy: myocardial necrosis or apoptosis? Acta Myol 2003;22:5-10.
67. Giglio V, Pasceri V, Messano L, et al. Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy. JACC 2003;42:309-16.
68. Mansi L, Pace L, Politano L, et al. Left ventricular function and perfusion in Becker muscular dystrophy. J Nucl Med 1997;38:563-71.
69. Mestroni L, Rocco C, Gregori D, et al. Familial dilated cardiomyopathy: Evidence for genetic and phenotypic heterogeneity. J Am Coll Cardiol 1999;34:181-90.
70. Donofrio PD, Challa VR, Hackshaw BT, et al. Cardiac transplant in a patient with muscular dystrophy and cardiomyopathy. Arch Neurol 1989;46:705-7.
71. Finsterer J, Bittner RE, Grimm M. Cardiac involvement in Becker's muscular dystrophy, necessitating heart transplantation, 6 years before apparent skeletal muscle involvement. Neuromusc Disord 1999;9:598-600.
72. Elliott P. Diagnosis and management of dilated cardiomyopathy. Heart 2000;84:106-12.
73. Noutsias M, Pauschinger M, Poller WC, et al. Immunomodulatory treatment strategies in inflammatory cardiomyopathy: current status and future perspectives. Expert Rev Cardiovasc Ther 2004;2:37-51.
74. Yuan Z, Shioji K, Kihara Y, et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 2004;286:H83.
75. Kashimura T, Hayashi M, Kodama M, et al. Effects of imidapril and TA-606 on rat dilated cardiomyopathy after myocarditis. Jpn Heart J 2003;44:735-44.
76. Nigro G, Comi LI, Nigro Ge, et al. Treatment of the cardiac dysrhythmias in skeletal muscle diseases: Preliminary data. Acta Myol 1999;3:237-41.
77. Spirito P, Seidmon CE, McKenna WJ, et al. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
78. Nigro G, Comi LI, Politano L, Nigro V. Dilated cardiomyopathy of muscular dystrophy: A multifaceted approach to management. Semin Neurol 1995;15:90-2.